CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.14
31.93%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

G1 Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.38
Open* 2.41
1-Year Change* -61.87%
Day's Range* 2.41 - 3.18
52 wk Range 1.08-8.40
Average Volume (10 days) 478.73K
Average Volume (3 months) 11.23M
Market Cap 84.35M
P/E Ratio -100.00K
Shares Outstanding 51.81M
Revenue 77.89M
EPS -1.47
Dividend (Yield %) N/A
Beta 1.75
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 6, 2023 2.38 0.54 29.35% 1.84 2.46 1.84
Dec 5, 2023 1.81 -0.16 -8.12% 1.97 1.97 1.79
Dec 4, 2023 1.97 -0.01 -0.51% 1.98 2.09 1.92
Dec 1, 2023 1.97 0.12 6.49% 1.85 1.97 1.78
Nov 30, 2023 1.86 0.16 9.41% 1.70 1.90 1.70
Nov 29, 2023 1.68 0.01 0.60% 1.67 1.74 1.66
Nov 28, 2023 1.67 0.06 3.73% 1.61 1.68 1.57
Nov 27, 2023 1.62 -0.05 -2.99% 1.67 1.67 1.61
Nov 24, 2023 1.67 0.04 2.45% 1.63 1.69 1.61
Nov 22, 2023 1.63 0.00 0.00% 1.63 1.67 1.59
Nov 21, 2023 1.61 0.01 0.63% 1.60 1.69 1.55
Nov 20, 2023 1.60 0.04 2.56% 1.56 1.87 1.54
Nov 17, 2023 1.53 -0.01 -0.65% 1.54 1.54 1.49
Nov 16, 2023 1.54 -0.04 -2.53% 1.58 1.60 1.51
Nov 15, 2023 1.61 0.03 1.90% 1.58 1.73 1.58
Nov 14, 2023 1.59 0.16 11.19% 1.43 1.59 1.43
Nov 13, 2023 1.42 0.05 3.65% 1.37 1.44 1.34
Nov 10, 2023 1.38 0.02 1.47% 1.36 1.41 1.29
Nov 9, 2023 1.31 -0.15 -10.27% 1.46 1.53 1.29
Nov 8, 2023 1.43 -0.10 -6.54% 1.53 1.54 1.40

G1 Therapeutics Events

Time (UTC) Country Event
Wednesday, February 28, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 G1 Therapeutics Inc Earnings Release
Q4 2023 G1 Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 51.301 31.476 45.285 0 0
Revenue 51.301 31.476 45.285 0 0
Total Operating Expense 187.479 173.733 141.761 129.041 89.286
Selling/General/Admin. Expenses, Total 101.033 96.491 69.445 40.648 18.603
Research & Development 82.698 75.426 72.316 88.393 70.683
Operating Income -136.178 -142.257 -96.476 -129.041 -89.286
Other, Net 0.003 -0.546 -0.542 6.594 3.998
Net Income Before Taxes -145.859 -147.427 -97.844 -122.447 -85.288
Net Income After Taxes -147.559 -148.352 -99.254 -122.447 -85.288
Net Income Before Extra. Items -147.559 -148.352 -99.254 -122.447 -85.288
Net Income -147.559 -148.352 -99.254 -122.447 -85.288
Total Adjustments to Net Income 0 0 0
Income Available to Common Excl. Extra. Items -147.559 -148.352 -99.254 -122.447 -85.288
Income Available to Common Incl. Extra. Items -147.559 -148.352 -99.254 -122.447 -85.288
Dilution Adjustment
Diluted Net Income -147.559 -148.352 -99.254 -122.447 -85.288
Diluted Weighted Average Shares 43.6261 41.9434 37.878 37.4993 33.3167
Diluted EPS Excluding Extraordinary Items -3.38235 -3.53696 -2.62036 -3.26532 -2.55992
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -3.38235 -3.54005 -2.62036 -3.26532 -2.55992
Interest Income (Expense), Net Non-Operating -9.684 -4.624 -0.826
Cost of Revenue, Total 3.748 2.016
Gross Profit 47.553 29.46
Unusual Expense (Income) -0.2
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 42.392 12.946 10.25 23.576 10.573
Revenue 42.392 12.946 10.25 23.576 10.573
Cost of Revenue, Total 1.404 1.459 0.992 1.111 0.976
Gross Profit 40.988 11.487 9.258 22.465 9.597
Total Operating Expense 30.876 38.692 41.137 45.124 47.535
Selling/General/Admin. Expenses, Total 17.432 21.753 23.558 24.432 25.716
Research & Development 12.04 15.48 16.587 19.581 20.843
Operating Income 11.516 -25.746 -30.887 -21.548 -36.962
Interest Income (Expense), Net Non-Operating -2.067 -2.373 -2.518 -2.553 -2.357
Other, Net 0.569 0.524 0.237 0.048 -0.127
Net Income Before Taxes 10.018 -27.595 -33.168 -24.053 -39.446
Net Income After Taxes 8.71 -27.595 -33.649 -25.272 -39.446
Net Income Before Extra. Items 8.71 -27.595 -33.649 -25.272 -39.446
Net Income 8.71 -27.595 -33.649 -25.272 -39.446
Income Available to Common Excl. Extra. Items 8.71 -27.595 -33.649 -25.272 -39.446
Income Available to Common Incl. Extra. Items 8.71 -27.595 -33.649 -25.272 -39.446
Diluted Net Income 8.71 -27.595 -33.649 -25.272 -39.446
Diluted Weighted Average Shares 61.0405 51.6479 46.309 42.7993 42.7077
Diluted EPS Excluding Extraordinary Items 0.14269 -0.53429 -0.72662 -0.59048 -0.92363
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.14269 -0.53429 -0.72662 -0.59048 -0.92363
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 179.5 243.565 216.392 271.003 370.133
Cash and Short Term Investments 145.07 221.186 207.306 269.208 369.29
Cash & Equivalents 94.594 221.186 207.306 269.208 369.29
Prepaid Expenses 7.094 13.157 8.786 1.732 0.843
Total Assets 187.965 254.094 228.552 284.831 371.27
Property/Plant/Equipment, Total - Net 7.951 9.048 10.508 13.391 1.137
Property/Plant/Equipment, Total - Gross 9.777 10.344 11.335 14.068 1.459
Accumulated Depreciation, Total -1.826 -1.296 -0.827 -0.677 -0.322
Total Current Liabilities 35.588 27.613 23.443 19.769 12.362
Accounts Payable 7.431 2.897 3.572 3.684 3.377
Accrued Expenses 26.692 24.295 17.474 16.085 8.985
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.465 0.421 2.397
Total Liabilities 119.218 110.553 51.201 29.304 12.45
Total Long Term Debt 77.015 75.19 19.893 0 0
Total Equity 68.747 143.541 177.351 255.527 358.82
Redeemable Preferred Stock
Common Stock 0.005 0.004 0.004 0.004 0.004
Retained Earnings (Accumulated Deficit) -732.018 -584.459 -436.107 -336.853 -214.406
Treasury Stock - Common -0.008 -0.008 -0.008 -0.008 -0.008
Total Liabilities & Shareholders’ Equity 187.965 254.094 228.552 284.831 371.27
Total Common Shares Outstanding 51.4994 42.5621 38.1141 37.6116 37.2421
Other Liabilities, Total 6.615 7.75 7.865 9.535 0.088
Additional Paid-In Capital 800.768 728.004 613.462 592.384 573.23
Other Current Assets, Total 0.063 0.063 0.063 0.063
Other Long Term Assets, Total 0.514 1.481 1.652 0.437
Total Receivables, Net 11.094 5.688 0.237
Accounts Receivable - Trade, Net 11.094 5.688 0.237
Long Term Debt 77.015 75.19 19.893
Total Inventory 16.179 3.471
Short Term Investments 50.476
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 126.103 140.436 153.965 179.5 157.465
Cash and Short Term Investments 94.352 104.231 116.317 145.07 122.982
Cash & Equivalents 52.623 55.914 68.237 94.594 93.238
Total Receivables, Net 9.265 13.171 16.025 11.094 10.521
Accounts Receivable - Trade, Net 9.265 13.171 16.025 11.094 10.521
Total Inventory 13.491 15.6 15.543 16.179 13.95
Prepaid Expenses 8.932 7.371 6.017 7.094 9.949
Other Current Assets, Total 0.063 0.063 0.063 0.063 0.063
Total Assets 133.097 147.891 161.957 187.965 166.573
Property/Plant/Equipment, Total - Net 6.78 7.173 7.564 7.951 8.365
Property/Plant/Equipment, Total - Gross 8.995 9.261 9.522 9.777 10.054
Accumulated Depreciation, Total -2.215 -2.088 -1.958 -1.826 -1.689
Other Long Term Assets, Total 0.214 0.282 0.428 0.514 0.743
Total Current Liabilities 33.653 33.912 33.69 35.588 37.134
Accounts Payable 7.335 5.762 5.38 7.431 8.442
Accrued Expenses 24.181 24.681 22.767 26.692 27.251
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.137 3.469 5.543 1.465 1.441
Total Liabilities 90.075 90.343 116.969 119.218 120.608
Total Long Term Debt 51.246 50.936 77.47 77.015 76.558
Long Term Debt 51.246 50.936 77.47 77.015 76.558
Other Liabilities, Total 5.176 5.495 5.809 6.615 6.916
Total Equity 43.022 57.548 44.988 68.747 45.965
Common Stock 0.005 0.005 0.005 0.005 0.004
Additional Paid-In Capital 812.132 808.454 804.604 800.768 744.338
Retained Earnings (Accumulated Deficit) -769.107 -750.903 -759.613 -732.018 -698.369
Treasury Stock - Common -0.008 -0.008 -0.008 -0.008 -0.008
Total Liabilities & Shareholders’ Equity 133.097 147.891 161.957 187.965 166.573
Total Common Shares Outstanding 51.8099 51.7085 51.6593 51.4994 42.8971
Short Term Investments 41.729 48.317 48.08 50.476 29.744
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -147.559 -148.352 -99.254 -122.447 -85.288
Cash From Operating Activities -128.62 -132.108 -83.742 -99.571 -74.307
Cash From Operating Activities 0.53 0.469 0.582 0.356 0.175
Non-Cash Items 23.716 24.613 19.006 16.449 10.233
Changes in Working Capital -5.307 -8.838 -4.076 6.071 0.573
Cash From Investing Activities -50.529 0 0.152 -2.716 -0.709
Capital Expenditures -0.506 0 -2.716 -0.709
Cash From Financing Activities 52.495 145.863 21.688 2.705 340.494
Financing Cash Flow Items -0.043 -1.411 -0.62 0 -0.892
Issuance (Retirement) of Stock, Net 52.538 92.274 2.308 2.705 341.386
Net Change in Cash -126.654 13.755 -61.902 -99.582 265.478
Cash Interest Paid 7.924 2.908 0.997
Other Investing Cash Flow Items, Total -50.023 0 0.152
Issuance (Retirement) of Debt, Net 0 55 20
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -27.595 -147.559 -113.91 -88.638 -49.192
Cash From Operating Activities -29.053 -128.62 -97.988 -76.741 -38.184
Cash From Operating Activities 0.132 0.53 0.393 0.254 0.115
Non-Cash Items 4.75 23.716 18.876 13.433 7.071
Cash Interest Paid 2.512 7.924 5.61 3.537 1.716
Changes in Working Capital -6.34 -5.307 -3.347 -1.79 3.822
Cash From Investing Activities 2.91 -50.529 -30.167 -0.506 0
Capital Expenditures -0.506 -0.506 -0.506
Cash From Financing Activities -0.214 52.495 0.145 0.018 0.018
Financing Cash Flow Items -0.215 -0.043 0 0 0
Issuance (Retirement) of Stock, Net 0.001 52.538 0.145 0.018 0.018
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash -26.357 -126.654 -128.01 -77.229 -38.166
Other Investing Cash Flow Items, Total 2.91 -50.023 -29.661 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Eshelman Ventures LLC Corporation 8.7275 4516074 1076923 2023-03-31
MedImmune Ventures, Inc. Venture Capital 5.7022 2950630 0 2023-03-31 LOW
Fisher Investments Investment Advisor/Hedge Fund 4.9144 2543006 -181704 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.7686 1950068 -29660 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 3.5172 1820015 -29832 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.1624 1118965 -57089 2023-06-30 LOW
Raymond James & Associates, Inc. Research Firm 1.7891 925776 133662 2023-09-30 LOW
D. E. Shaw & Co., L.P. Hedge Fund 1.1914 616503 186864 2023-06-30 MED
Millennium Management LLC Hedge Fund 1.1751 608065 -267069 2023-06-30 HIGH
Renaissance Technologies LLC Hedge Fund 1.105 571791 128816 2023-06-30 HIGH
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.9523 492776 209541 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8342 431652 -6742 2023-06-30 LOW
Tekla Capital Management LLC Investment Advisor 0.8191 423869 0 2023-06-30 LOW
BofA Global Research (US) Research Firm 0.6191 320346 -283072 2023-06-30 LOW
GSA Capital Partners LLP Hedge Fund 0.5141 266017 266017 2023-06-30 HIGH
Bailey (John E JR) Individual Investor 0.4778 247252 -2719 2023-07-05 MED
Charles Schwab Investment Management, Inc. Investment Advisor 0.4631 239609 35245 2023-06-30 LOW
Needham Investment Management L.L.C. Investment Advisor/Hedge Fund 0.4522 234000 0 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.4362 225700 225700 2022-12-31 LOW
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.4294 222182 -133 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

G1 Therapeutics Company profile

About G1 Therapeutics Inc

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The Company's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, G1 Therapeutics Inc revenues decreased 30% to $31.5M. Net loss increased 49% to $148.4M. Revenues reflect License revenue decrease of 55% to $20.4M. Higher net loss reflects General and Administrative - Balancing increase of 40% to $77.6M (expense), Stock-based Compensation in SGA increase of 45% to $17.3M (expense), Research & Development - Balancing value increase of 8% to $70.6M (expense).

Industry: Bio Therapeutic Drugs

700 Park Offices Drive
Suite 200
RESEARCH TRIANGLE PARK
NORTH CAROLINA 27709
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

US100

15,997.80 Price
+1.310% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.65 Price
+0.990% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,031.44 Price
+0.260% 1D Chg, %
Long position overnight fee -0.0197%
Short position overnight fee 0.0115%
Overnight fee time 22:00 (UTC)
Spread 0.50

Oil - Crude

70.33 Price
+1.240% 1D Chg, %
Long position overnight fee -0.0205%
Short position overnight fee -0.0014%
Overnight fee time 22:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading